Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL203271 | 1.00 | KIF11 (0.42) | KIF11SMN1; SMN2ALDH1A1CYP2C9CA1 | |
| Hydrochloric Acid SCHEMBL2132352 | 1.00 | KIF11 (0.42) | KIF11SMN1; SMN2ALDH1A1CYP2C9CA1 | |
| SCHEMBL110066 | 0.98 | — | — | |
| SCHEMBL2692924 | 0.98 | — | — | |
| SCHEMBL16471260 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL1565157 | 0.86 | KIF11 (0.42) | KIF11SMN1; SMN2ALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL2801871 | 0.86 | KIF11 (0.42) | KIF11SMN1; SMN2ALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL29401888 | 0.86 | KIF11 (0.42) | KIF11SMN1; SMN2ALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL1819809 | 0.86 | KIF11 (0.42) | KIF11SMN1; SMN2ALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL1565156 | 0.86 | KIF11 (0.42) | KIF11SMN1; SMN2ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3805237-B1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | JIANGSU CHUANGTE PHARMACEUTICAL TECH CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| CN-115785137-A | Synthesis and application of peptide borate compound | 江苏正大丰海制药有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| CN-112384519-B | Synthesis and application of peptide borate compound | 江苏正大丰海制药有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3805237-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| CN-112384519-A | Synthesis and application of peptide borate compound | 江苏正大丰海制药有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-110540547-A | Synthesis and application of peptide borate compound | QIN YANRU | 2019-12-06 | — | — | CN | disclosed |
| WO-2019228299-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | 江苏正大丰海制药有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| US-20180273553-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2018-09-27 | — | — | US | disclosed |
| EP-3280717-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016164814-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| CN-105732683-A | Dipeptide boric acid composed of carboxylic acid and alpha-amino acid as well as ester compound thereof, and preparation method and application of dipeptide boric acid and ester compound thereof | 南京林业大学 | 2016-07-06 | — | — | CN | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2012103113-A1 | PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C | GILEAD PHARMASSET, LLC (US) | 2012-08-02 | — | — | WO | disclosed |
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| EP-1963262-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007069020-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | CA2 4824/4885KIF11 4102/4885SMN1; SMN2 4051/4885 |
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | SEM1, VIP, PSMB11 | CA2 2731/4885KIF11 2581/4885SMN1; SMN2 2110/4885 |
| US-20180273553-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | CA2 321/4885KIF11 3712/4885SMN1; SMN2 3037/4885 |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | CA2 2397/4885KIF11 3472/4885SMN1; SMN2 3691/4885 |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | SEM1, VIP, PSMB11 | CA2 2731/4885KIF11 2581/4885SMN1; SMN2 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.